To enhance these prognoses, the Selecting Therapeutic Targets in Inflammatory Bowel Disease-II has proposed short-term, intermediate-term, and long-term goals, including symptom control and normalization of C-reactive protein (CRP) levels, reduction in fecal calprotectin (a marker reflecting the degree of intestinal inflammation), and endoscopic healing, respectively.[7]. This evidence concerns the gene CRP and inflammation.